title: alpha-IFN treatment does not induce Ki-ras expression in hairy-cell leukemia patients.
abstract: alpha-Interferon (IFN) is effective in the treatment of hairy-cell leukemia (HCL), but the treatment is sometimes over a long period. Biological changes such as the increase of tumorigenicity can occur rapidly in vivo as a result of beginning this treatment; an increase in c-Ki-ras oncogene expression has also been observed. In order to determine whether the findings observed in vitro would be duplicated in an in vivo system, we decided to analyze the Ki-ras RNA and protein levels in the lymphocytes of three HCL patients, compared with these levels in seven normal donors and one non-treated HCL patients. Ki-ras was not activated by IFN, at least not in lymphocytes. Therefore, the data suggest that the drug could be used for long-term therapy with relatively low risk to the patients.
authors.affiliation: LOI CNRS, Laboratoire de Virologie des Leucémies, Paris, France.
authors.forename: M L
authors.initials: ML
authors.lastname: Giron
authors.forename: G
authors.initials: G
authors.lastname: Mercier
authors.forename: F
authors.initials: F
authors.lastname: Sigaux
authors.forename: S
authors.initials: S
authors.lastname: Castaigne
authors.forename: G
authors.initials: G
authors.lastname: Flandrin
authors.forename: L
authors.initials: L
authors.lastname: Degos
authors.forename: R
authors.initials: R
authors.lastname: Emanoïl-Ravier
mesh_terms: D005786:Gene Expression Regulation / Q000187:drug effects*; D011905:Genes, ras / Q000187:drug effects*; D006801:Humans; D007370:Interferon Type I / Q000627:therapeutic use*; D007943:Leukemia, Hairy Cell / Q000235:genetics* / Q000628:therapy; D011518:Proto-Oncogene Proteins / Q000096:biosynthesis; D011994:Recombinant Proteins
chemical_list: D007370:Interferon Type I; D011518:Proto-Oncogene Proteins; D011994:Recombinant Proteins